Table 2.
Univariate comparison of demographic and tumor-related characteristics between pCR and non-pCR patients
| Characteristic | Patients with pCR, number (%) or median (IQR) | Patients with non-pCR, number (%) or median (IQR) | P value |
|---|---|---|---|
| Overall population | 16 (40) | 24 (60) | -- |
| Age (years), median | 45.5 (35.5–51.5) | 49.5 (34.3–53.0) | 0.97 |
| BMI (kg/m2), median | 25.7 (23.3–29.6) | 27.3 (24.2–31.0) | 0.49 |
| Race | 0.63 | ||
| White | 15 (93.8) | 20 (83.3) | |
| Black/Asian/Hispanic | 1 (6.2) | 4 (16.7) | |
| Charlson comorbidity index | 0.75 | ||
| <2 (mild) | 7 (43.8) | 9 (37.5) | |
| ≥2 (moderate–high) | 9 (56.2) | 15 (62.5) | |
| Menopausal status | 1.00 | ||
| Premenopausal | 9 (56.2) | 14 (58.3) | |
| Postmenopausal | 7 (43.8) | 10 (41.7) | |
| AJCC clinical stageb | 0.12 | ||
| II | 11 (68.8) | 10 (41.7) | |
| III | 5 (31.2) | 14 (58.3) | |
| ER/PR statusb | 0.02 | ||
| Positive | 5 (31.2) | 17 (70.8) | |
| Negative | 11 (68.8) | 7 (29.2) | |
| Lymphovascular invasion | 0.21 | ||
| Absent | 15 (93.8) | 18 (75.0) | |
| Present | 1 (6.2) | 6 (25.0) | |
| Nuclear grade | 0.33 | ||
| Grade 1/2 | 4 (25.0) | 10 (41.7) | |
| Grade 3 | 12 (75.0) | 14 (58.3) | |
| Neoadjuvant regimen | 1.00 | ||
| AC/TH | 13 (81.3) | 20 (83.3) | |
| Othera | 3 (18.7) | 4 (16.7) | |
| Operative approachb | 0.09 | ||
| BCS + XRT | 8 (50.0) | 5 (20.8) | |
| Mastectomy ± XRT | 8 (50.0) | 19 (79.2) |
aOther included carboplatin/taxotere/trastuzumab and taxotere/cyclophosphamide/trastuzumab. bIncluded in multivariable logistic regression analysis to determine independent correlates to pCR. pCR pathologic complete response, BMI body mass index, AJCC American Joint Committee on Cancer, ER estrogen receptor, PR progesterone receptor, AC/TH Adriamycin/Cytoxan/Taxol/Herceptin, BCS breast-conserving surgery, XRT radiotherapy